Mineralys Therapeutics(NASDAQ) MLYS

Mineralys helps people with high blood pressure that other medicines cannot fix. Their medicine blocks a specific hormone that can damage the heart. This treatment aims to lower the risk of strokes and kidney disease.

Pills, Pressure, and Patents

• Lorundrostat: An oral pill that blocks the production of aldosterone, a hormone that regulates salt and water in the body.
• Hypertension Treatment: Therapy for patients with uncontrolled or resistant high blood pressure who do not respond to standard treatments.
• Cardiorenal Research: Studies focused on using the company drug to treat chronic kidney disease and breathing issues during sleep.

The Path to Approval

• In July 2020, the company obtained an exclusive worldwide license for its lead drug from Tanabe Pharma Corporation.
• Mineralys submitted a New Drug Application to the U.S. Food and Drug Administration in December 2025 for the treatment of high blood pressure.
• A sales agreement for up to $300 million in stock was started in November 2025 with BofA Securities, Inc., Evercore Group L.L.C., and Goldman Sachs & Co. LLC.
• In March 2026, the company reported results from its Phase 2 trial evaluating drug effects on patients with sleep apnea and high blood pressure.

How They Target Disease

Mineralys focuses on a specific biological pathway by blocking a hormone that current drugs often miss. The company has moved from its 2019 founding to filing for federal drug approval by completing six clinical trials.

Counting the Costs

• Operating loss reached $45.3 million in Q1 2026, a 2% deepening from $44.4 million in Q1 2025.
• Net loss was $39.3 million in Q1 2026, an improvement of 6.8% from the $42.2 million loss in Q1 2025.
• Total cash, cash equivalents, and investments were $646.1 million as of March 31, 2026.
• The company raised $20.2 million from stock sales during the first three months of 2026.

The Final Word

Mineralys has evolved from a research startup to a clinical-stage firm awaiting a federal decision on its primary blood pressure drug. Its future depends on the successful commercial launch of its lead candidate and the management of its substantial cash reserves.